Amgen ( (AMGN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen shares slipped as investors reacted cautiously to clinical trial news that lacked immediate commercial impact. The company is advancing a Phase 3 study testing whether a simpler under-the-skin version of gout drug KRYSTEXXA can match the effectiveness of the current IV form when used with oral methotrexate.
The trial targets hard-to-treat gout patients and will measure if uric acid levels stay at goal by Month 6, a key efficacy marker closely watched by the market. Amgen updated the study record on Feb. 27, 2026, but did not announce major milestones, leaving some traders disappointed and adding pressure to the stock.
More about Amgen
YTD Price Performance: 19.41%
Average Trading Volume: 2,920,161
Technical Sentiment Signal: Buy
Current Market Cap: $209.2B
For further insights into AMGN stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.